In conclusion, our comparisons of the mutational landscape between 11q23/KMT2A‐rearranged AML and non‐11q23/KMT2A‐rearranged AML revealed the relatively high frequency of mutations in the RAS signaling pathway and SETD2 in 11q23/KMT2A‐rearranged pediatric AML, suggesting that both gene mutations mentioned above should be incorporated into screening tests for prognostication. Here, SETD2 is linked to acute myeloid leukemia.